Sign In
Buy IMNN
$2.10
-0.0400 (-1.87%)
At Close: Jun 03, 2026
Why VTSI Stock AND CLSN Stock Are Trading Lower Today
02:42pm, Wednesday, 31'st Mar 2021
Virtra Inc (NASDAQ: VTSI) shares are trading lower by 22% Wednesday after the company priced a registered direct offering at $6 per share. VirTra is engaged in the sale and development of the judgmen
Celsion Corporation (CLSN) CEO Michael Tardugno on Q4 2020 Results - Earnings Call Transcript
02:02pm, Friday, 19'th Mar 2021
Celsion Corporation (CLSN) CEO Michael Tardugno on Q4 2020 Results - Earnings Call Transcript
Celsion Corporation Reports 2020 Financial Results and Provides Business Update
08:45am, Friday, 19'th Mar 2021
Entered 2021 with a Focus on Cancer Immunotherapy and Next-Generation Infectious Vaccines and a Strong Balance Sheet
Earnings Previews: FedEx, Luminar, Nike, Celsion
01:10pm, Wednesday, 17'th Mar 2021
Wednesday afternoon's and Thursday morning's noteworthy earnings reports were included in our Tuesday preview covering scheduled reports from electric pickup maker Lordstown Motors, cannabis producers
Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021
08:45am, Friday, 12'th Mar 2021
LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announ
8 Biotech Penny Stocks for Investors to Watch
11:54am, Wednesday, 10'th Mar 2021
Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.
Do Options Traders Know Something About Celsion (CLSN) Stock We Don't?
09:09am, Friday, 05'th Mar 2021
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
LAWRENCEVILLE, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today
Celsion Corporation to Participate in the Virtual 33ʳᵈ Annual Roth Conference
08:45am, Friday, 26'th Feb 2021
LAWRENCEVILLE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today a
Celsion's Ovarian Cancer Immunotherapy Shows 38% Improvement In R0 Resection Rates Versus Control Arm
11:34am, Thursday, 25'th Feb 2021
Celsion Corporation (NASDAQ: CLSN) reports interim observations and provides an update on its Phase 1/2 OVATION 2 study with GEN-1 in newly diagnosed patients with stage 3/4 ovarian cancer. GEN-1
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
08:00am, Tuesday, 23'rd Feb 2021
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years
CLSN Stock Price Increases Over 50% Pre-Market: Why It Happened
08:24am, Monday, 22'nd Feb 2021
The stock price of Celsion Corporation (NASDAQ: CLSN) is trading at over 50% pre-market. This is why it happened.
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer
07:30am, Monday, 22'nd Feb 2021
Celsion's Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases Granted an Accelerated Development Pathway
Celsion Corporation Announces Formation of Vaccine Advisory Board
08:30am, Friday, 12'th Feb 2021
Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2
